Abbott Labs Sells Developed Markets Generics Unit

July 14 (Bloomberg) -- Marshall Sonenshine, chairman and managing partner at Sonenshine Partners, and Jonathan Golub, chief U.S. market strategist at RBC Capital Markets, examine Abbott Laboratories selling its developed markets generic drug unit to Mylan in a deal worth $5.3 Billion and what it means to the current M&A market. They speak on “Bloomberg Surveillance.”
The Benefits of EMV Credit Card Chip Technology
48:43 - Ellen Richey, Visa's chief enterprise risk officer, explains the benefits of EMV credit card chip technology. She speaks with Bloomberg's Emily Chang on "Bloomberg West." (Source: Bloomberg)
  • ‘The Martian’: $108 Million Movie Debuts This Weekend
  • What’s Behind the Labor Market is Slow Down?
  • How GE Is Appealing to the Tech Audience